Company research
Gain Therapeutics, Inc.
CIK 1819411Updated Sep 27, 2026
SecurityGANX · NASDAQ · equity
GANX price & chart
Loading TradingView…
NASDAQ:GANX on TradingView ↗About the company
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
In the news
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference ↗
Recent filings
Show 5 more recent filings
4 filing
4 filing
4 filing
Other Events
Items 8.01
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 22,818,975Source | 12,123,884Source | 18,609,331Source | 24,099,387Source |
| Property, Plant and Equipment, NetUSD | 74,916Source | 103,619Source | 125,962Source | 144,379Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,837,628Source | 10,385,863Source | 11,794,949Source | 7,311,611Source |
| Assets, CurrentUSD | 22,237,138Source | 11,602,478Source | 17,778,868Source | 21,091,296Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,219,809Source | 945,536Source | 741,638Source | 848,854Source |
| Operating Lease, Right-of-Use AssetUSD | 334,090Source | 219,715Source | 459,215Source | 659,933Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,254,227Source | 4,784,310Source | 6,031,107Source | 5,219,873Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 4,209Source | 2,713Source | 1,621Source | 1,189Source |
| Additional Paid in CapitalUSD | 119,139,677Source | 88,779,318Source | 73,113,079Source | 57,358,895Source |
| Retained Earnings (Accumulated Deficit)USD | -81,194,908Source | -60,783,717Source | -38,516,197Source | -20,925,459Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 776,869Source | -247,549Source | 247,241Source | 35,627Source |
| Stockholders' Equity Attributable to ParentUSD | 18,564,748Source | 7,339,574Source | 12,578,224Source | 18,879,514Source |
| Liabilities and EquityUSD | 22,818,975Source | 12,123,884Source | 18,609,331Source | 24,099,387Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,352,396Source | 3,911,321Source | 4,949,959Source | 4,125,251Source |
| Operating Lease, Liability, CurrentUSD | 119,876Source | 160,913Source | 229,693Source | 229,080Source |
| Accounts Payable, CurrentUSD | 825,027Source | 946,259Source | 1,318,965Source | 1,626,100Source |
| Operating Lease, Liability, NoncurrentUSD | 211,238Source | 53,598Source | 229,855Source | 441,784Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 1,016,582Source | 1,082,091Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 16,800,000Source | — |
| Long-term DebtUSD | 400,953Source | 438,504Source | 567,850Source | 603,393Source |
| Long-term Debt, Current MaturitiesUSD | 100,869Source | 110,177Source | 118,797Source | 108,135Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 300,084Source | 328,327Source | 449,053Source | 495,258Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -20,161,099Source | -20,411,191Source | -22,267,520Source | -17,590,738Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 94,046Source | 84,071Source | 83,579Source | 64,168Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,803,195Source | 2,390,159Source | 3,259,026Source | 1,526,434Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | -643,164Source | 1,066,707Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -18,465,432Source | -18,873,827Source | -18,865,873Source | -14,692,139Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 4,977,507Source | 10,222,667Source | -14,774,813Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 28,447,766Source | 13,012,076Source | 12,641,343Source | -78,774Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 10,456,366Source | -1,411,412Source | 4,486,541Source | -29,569,523Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,873,924Source | 10,417,558Source | 11,828,970Source | 7,342,429Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 47,549Source | 86,309Source | 134,962Source | 2,740Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 474,032Source | -527,168Source | 488,404Source | -23,797Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,803,195Source | 2,390,159Source | 3,259,026Source | 1,526,434Source |
| Capitalized Computer Software, AmortizationUSD | 49,000Source | 47,000Source | 45,507Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 16,800,000Source | — |
| DepreciationUSD | 45,000Source | 38,000Source | 34,875Source | 26,632Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -833,673Source | 119,120Source | -429,346Source | -96,074Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -619,800Source | — | — | — |
| General and Administrative ExpenseUSD | 8,497,920Source | 9,559,534Source | 10,787,700Source | 9,539,863Source |
| Income Tax Expense (Benefit)USD | 861,118Source | 536,815Source | 79,275Source | 92,976Source |
| Net Income (Loss) Attributable to ParentUSD | -20,161,099Source | -20,411,191Source | -22,267,520Source | -17,590,738Source |
| Operating ExpensesUSD | 18,710,702Source | 20,350,592Source | 22,308,313Source | 17,917,153Source |
| Operating Lease, ExpenseUSD | — | — | 246,165Source | 228,739Source |
| Proceeds from Stock Options ExercisedUSD | 250,260Source | 57,711Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 55,180Source | 132,640Source |
| Operating Income (Loss)USD | -18,710,702Source | -20,350,592Source | -22,253,133Source | -17,777,045Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -19,299,981Source | -19,874,376Source | -22,188,245Source | -17,497,762Source |
| Income Tax Expense (Benefit)USD | 861,118Source | 536,815Source | 79,275Source | 92,976Source |
| Net Income (Loss) Attributable to ParentUSD | -20,161,099Source | -20,411,191Source | -22,267,520Source | -17,590,738Source |
| Earnings Per Share, BasicUSD per share | -0.61Source | -0.89Source | -1.71Source | -1.48Source |
| Earnings Per Share, DilutedUSD per share | -0.61Source | -0.89Source | -1.71Source | -1.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 32,968,336Source | 22,881,415Source | 13,011,361Source | 11,883,368Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,968,336Source | 22,881,415Source | 13,011,361Source | 11,883,368Source |
| Additional Financial Items | ||||
| Capitalized Computer Software, AmortizationUSD | 49,000Source | 47,000Source | 45,507Source | — |
| Current Income Tax Expense (Benefit)USD | 861,118Source | 536,815Source | 79,275Source | 92,976Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -833,673Source | 119,120Source | -429,346Source | -96,074Source |
| General and Administrative ExpenseUSD | 8,497,920Source | 9,559,534Source | 10,787,700Source | 9,539,863Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -22,476,104Source | -22,388,925Source | -22,477,695Source | -17,341,701Source |
| Interest Income (Expense), NetUSD | — | — | 494,234Source | 375,357Source |
| Interest Income (Expense), Nonoperating, NetUSD | 244,394Source | 357,096Source | — | — |
| Operating ExpensesUSD | 18,710,702Source | 20,350,592Source | 22,308,313Source | 17,917,153Source |
| Operating Lease, ExpenseUSD | — | — | 246,165Source | 228,739Source |
| Research and Development ExpenseUSD | 10,212,782Source | 10,791,058Source | 11,520,613Source | 8,377,290Source |
Filing attachments
ganx-20260811xex99d1.htm · 8-K · 2026-08-11
EX-99.1 2 ganx-20260811xex99d1.htm EX-99.1 Exhibit 99.1 Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update BETHESDA, Md., August 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate upda…
Read attachment ↗ganx-20260511xex99d1.htm · 8-K · 2026-05-11
EX-99.1 2 ganx-20260511xex99d1.htm EX-99.1 Exhibit 99.1 Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update BETHESDA, MD, May 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. …
Read attachment ↗ganx-20260326xex99d1.htm · 8-K · 2026-03-26
EX-99.1 2 ganx-20260326xex99d1.htm EX-99.1 Exhibit 99.1 Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, …
Read attachment ↗tm269191d1_ex99-1.htm · 8-K · 2026-03-18
EX-99.1 2 tm269191d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC - an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine Additional MDS-UPDRS data …
Read attachment ↗tm265021d1_ex99-1.htm · 8-K · 2026-02-03
EX-99.1 2 tm265021d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation September 2024 GAIN THERAPEUTICS Corporate Deck February 2026 NASDAQ: GANX ────────────────────────── © © 2 0 2 6 2 0 2 5 - -G AG A I N T H E R A P E U T I C S I N T H E R A P E U T I C S 22 Certain statements set forth in this presentation are forward-looking and reflect the Company’s plans, beliefs, expectations and current views with respect to, among other things, future events and financi…
Read attachment ↗ganx-20251112xex99d1.htm · 8-K · 2025-11-12
EX-99.1 2 ganx-20251112xex99d1.htm EX-99.1 Exhibit 99.1 Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson’s Disease with or without GBA1 mutations during 3Q 2025 Received approva…
Read attachment ↗